|Bid||0.00 x 1100|
|Ask||0.00 x 29200|
|Day's range||8.95 - 9.32|
|52-week range||6.25 - 13.76|
|Beta (5Y monthly)||1.50|
|PE ratio (TTM)||2,322.50|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||12.19|
Over the past 55 years, few if any investors have held a candle to the returns that Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett has generated for his investors. The thing is, there are a handful of stocks currently in Warren Buffett's investment portfolio that look to be valued at bargain-basement prices. The interesting thing about money-center bank Wells Fargo (NYSE: WFC), which Buffett has held for roughly three decades, is that Berkshire Hathaway has aggressively sold it in recent years.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that results from the 52-week, multicenter, randomized, double-blind, parallel group study evaluating monthly or quarterly AJOVY® (fremanezumab-vfrm) injection in adults with chronic migraine (CM) or episodic migraine (EM), were published online ahead of print in Neurology.
Warren Buffett's investing acumen is legendary -- but he's not behind every stock in Berkshire Hathaway's portfolio.